Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Equity Ratio: 2022-2025

Historic Equity Ratio for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to 0.77.

  • bioAffinity Technologies' Equity Ratio rose 61.86% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year increase of 61.86%. This contributed to the annual value of 0.40 for FY2024, which is 32.36% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Equity Ratio stood at 0.77, which was up 271.48% from -0.45 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Equity Ratio high stood at 0.92 for Q1 2023, and its period low was -0.45 during Q2 2025.
  • Moreover, its 3-year median value for Equity Ratio was 0.59 (2023), whereas its average is 0.52.
  • Data for bioAffinity Technologies' Equity Ratio shows a peak YoY increase of 61.86% (in 2025) and a maximum YoY decrease of 187.17% (in 2025) over the last 5 years.
  • bioAffinity Technologies' Equity Ratio (Quarterly) stood at 0.91 in 2022, then slumped by 34.86% to 0.59 in 2023, then plummeted by 32.36% to 0.40 in 2024, then skyrocketed by 61.86% to 0.77 in 2025.
  • Its Equity Ratio was 0.77 in Q3 2025, compared to -0.45 in Q2 2025 and 0.26 in Q1 2025.